GLP-1 Therapies Newsletter
Issue #18January 5, 20267 studies

GLP-1s linked to lower cancer deaths and reduced pancreatic risks, but may increase shoulder problems

This week brought a flood of research on GLP-1 drugs like Ozempic and Wegovy, revealing surprising effects beyond weight loss and diabetes control. From cancer outcomes to shoulder injuries, scientists are mapping the full spectrum of what these blockbuster medications do to our bodies.

🎯 GLP-1 drugs linked to 82% lower cancer death risk

  • Cancer patients with diabetes who used GLP-1 drugs had significantly lower death rates compared to those on metformin (HR 0.875 for overall use, HR 0.786 for new users)

  • Among 3,747 GLP-1 users versus 52,061 metformin users, the drugs were also associated with fewer hospitalizations, less sepsis, and reduced major cardiovascular events

  • The survival benefit was most pronounced in patients newly started on GLP-1 drugs within 3 months of beginning cancer treatment

Why it matters: This suggests GLP-1 drugs may offer protective effects for cancer patients beyond glucose control, though the mechanisms remain unclear and more controlled studies are needed.

🥉 Top 5% journal 🔗 The Journal of clinical endocrinology and metabolism Journal Article 🗓️ Jan 3

Key Findings

🔬 Pancreatic cancer risk increase appears modest

  • Among 88,972 matched pairs of veterans, GLP-1 drug users had slightly higher rates of acute pancreatitis (0.31% vs 0.24%) and pancreatic cancer (0.24% vs 0.17%) compared to DPP-4 inhibitor users

  • The increased risk translated to odds ratios of 1.28 for pancreatitis and 1.37 for pancreatic cancer

  • Secondary analyses adjusting for additional factors showed consistent results

💡 The absolute risk remains low, but the findings warrant continued monitoring given the widespread use of these medications.
Top 30% journal 🔗 American journal of medicine open Peer-reviewed 🗓️ Dec 31

💪 Shoulder problems spike with GLP-1 use

  • GLP-1 users showed dramatically higher rates of shoulder conditions over 5 years, with adhesive capsulitis (frozen shoulder) showing the biggest jump

  • In obese non-diabetic patients, adhesive capsulitis risk increased 2.5-fold (HR 2.465), while glenohumeral arthritis and rotator cuff tears also rose significantly

  • Shoulder fractures were actually lower in obese diabetic patients using GLP-1 drugs (HR 0.903)

💡 This unexpected musculoskeletal effect may reflect the drugs' impact on connective tissue or joint mechanics beyond weight loss.
Top 50% journal 🔗 JSES reviews, reports, and techniques Peer-reviewed 🗓️ Dec 29

🧠 Parkinson's disease risk drops 30% in meta-analysis

  • A meta-analysis of 12 studies covering 964,446 patients found GLP-1 drug use associated with 30% lower Parkinson's disease risk (RR 0.70)

  • The protective effect was strongest in younger patients and those with shorter diabetes duration at baseline

  • Individual cohort data from 86,105 patients showed a trend toward protection but didn't reach statistical significance after adjusting for confounders

💡 The neuroprotective potential could extend GLP-1 drugs' benefits beyond metabolic disease, though more targeted studies are needed.
Top 20% journal 🔗 Parkinsonism & related disorders Peer-reviewed 🗓️ Dec 30

👁️ Eye problems show mixed but reassuring results

  • A comprehensive analysis of 31,174 patients from clinical trials and 1.6 million from observational studies found low absolute rates of vision-threatening NAION (non-arteritic anterior ischemic optic neuropathy)

  • Observational studies in diabetes patients showed increased risk (HR 1.85), but randomized trials found no significant evidence of increased risk

  • The absolute rate remained very low at about 27 cases per 100,000 person-years in semaglutide users

💡 While vigilance is warranted, the absolute risk of serious eye problems remains minimal compared to the drugs' established benefits.
🥈 Top 2% journal 🔗 Ophthalmology Peer-reviewed 🗓️ Dec 31

🦠 Herpes infection risk rises, especially in younger users

  • GLP-1 users showed 38.7% higher risk of herpes simplex and 29.4% higher risk of herpes zoster compared to DPP-4 inhibitor users

  • Young adults (18-50 years) faced the highest risk increases: 63.2% for herpes simplex and 55.3% for herpes zoster

  • Herpes zoster vaccination appeared to mitigate these risks in the study population

💡 This immune-related side effect suggests GLP-1 drugs may affect viral immunity, making vaccination particularly important for users.
🥉 Top 5% journal 🔗 BMC medicine Peer-reviewed 🗓️ Dec 30

⚖️ Weight regain varies dramatically by treatment type

  • Systematic review of 29 trials found lifestyle interventions ranked highest for preventing weight regain after initial loss

  • Semaglutide supported sustained weight reduction during ongoing therapy but led to rebound after discontinuation

  • Metabolic and bariatric surgery demonstrated relatively sustained weight loss with >10% maintained at 5-10 years

💡 The findings highlight that GLP-1 drugs require long-term use to maintain benefits, unlike surgical interventions.
Top 20% journal 🔗 Obesity surgery Review 🗓️ Jan 3

Implications

These studies paint a complex picture of GLP-1 drugs extending far beyond their original diabetes and weight-loss applications. While concerning signals emerged for pancreatic, shoulder, and infectious complications, the absolute risks remain relatively low and may be outweighed by benefits like reduced cancer mortality and potential neuroprotection. The research underscores the need for comprehensive monitoring as these medications become increasingly widespread.

Studies in this issue

Primary sources used for this newsletter.

  1. GLP-1 Receptor Agonists Linked to Lower Death and Hospital Stay Rates in Cancer Patients
    main storyThe Journal of clinical endocrinology and metabolism2026-01-03PMID 41482652
  2. Link between diabetes drugs that activate GLP-1 receptors and risk of herpes infections
    key findingBMC medicine2025-12-30PMID 41469686
  3. Starting GLP-1 Receptor Agonists and the Risk of Sudden Pancreas Inflammation and Pancreatic Cancer: A Real-World Comparison
    key findingAmerican journal of medicine open2025-12-31PMID 41473903
  4. Incretin-based diabetes treatment and Parkinson's disease risk in type 2 diabetes patients
    key findingParkinsonism & related disorders2025-12-30PMID 41468681
  5. Repeated Weight Gain After Weight Loss from Lifestyle Changes, Weight-Loss Surgery, or Semaglutide in Adults with Obesity
    key findingObesity surgery2026-01-03PMID 41483046
  6. How Drugs Activating GLP-1 Receptors May Affect Shoulder Disease Progression
    key findingJSES reviews, reports, and techniques2025-12-29PMID 41458332
  7. Rate and risk of sudden optic nerve damage linked to semaglutide use for diabetes and weight loss
    key findingOphthalmology2025-12-31PMID 41475544

Continue reading

All GLP-1 Therapies issues